TRANSPOSON THERAPEUTICS
Transposon Therapeutics operates as a pharmaceutical company based in Westport, Connecticut. It specializes in developing therapeutics for debilitating and life-threatening diseases
TRANSPOSON THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2019-01-01
Address:
Westport, Connecticut, United States
Country:
United States
Website Url:
http://www.transposonrx.com
Total Employee:
11+
Status:
Active
Technology used in webpage:
U.S. Server Location
Similar Organizations
Imagen Biotech
Imagen Biotech is focused on identifying and developing therapeutics for blinding diseases.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Modis Therapeutics
Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases.
Oralome
Oralome uses cutting edge technologies and therapeutics to enable precision health.
Revivo Therapeutics
Revivo Therapeutics is specializing in treating brain diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
StoreMyTumor
StoreMyTumor specializes in tumor preservation, advanced testing, and immune-therapy.
Strykagen
Strykagen manufactures transforming diagnostics and therapeutics for life-threatening rare muscle diseases.
TNeuroPharma
TNeuroPharma develops a therapeutic-based technology focusing on the T-cell contribution in tracking and treating neurodegenerative disease.
Current Advisors List
Current Employees Featured
Founder
Investors List
SV Health Investors
SV Health Investors investment in Seed Round - Transposon Therapeutics
Official Site Inspections
http://www.transposonrx.com Semrush global rank: 2.99 M Semrush visits lastest month: 5.25 K
- Host name: 253.24.180.107.host.secureserver.net
- IP address: 107.180.24.253
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Transposon Therapeutics"
Transposon Therapeutics - Crunchbase Company Profile & Funding
Transposon Therapeutics operates as a pharmaceutical company based in Westport, Connecticut. It specializes in developing therapeutics for debilitating and life-threatening diseasesSee details»
Transposon Company Profile 2024: Valuation, Funding …
Www.transposonrx.com. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. 4660 La Jolla Village Drive; Suites 100 and 200; San Diego, CA 92122; United States +1 (858) Primary …See details»
Transposon Therapeutics - Products, Competitors, Financials, …
Headquarters Location. 4660 La Jolla Village Drive Suites 100 and 200. San Diego, California, 92122, United States. 858-535-4821See details»
Transposon Therapeutics, Inc.
Nov 30, 2022 This Policy does not apply to third-party websites that are accessible through our Services, unless such website directs users or visitors to this Policy. When you click on one of …See details»
Transposon Receives US FDA Fast Track Designation for TPN-101 …
May 21, 2024 The designation of TPN-101 as a Fast Track product for PSP is supported by data from a Phase 2, randomized, double-blind, placebo-controlled study of TPN-101 in patients …See details»
Recommended Stories - Yahoo Finance
Feb 13, 2024 Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related …See details»
Transposon Therapeutics, Inc.
Frost B, Hemberg M, Lewis J, Feany MB. Tau promotes neurodegeneration through global chromatin relaxation. Nat Neurosci. 2014;17(3):357-366. doi:10.1038/nn.3639 ...See details»
Transposon Therapeutics - Canaan
Transposon Therapeutics, Inc. is developing TPN-101 (also known as Censavudine) and other LINE-1 reverse transcriptase inhibitors for the treatment of rare neurodegenerative diseases …See details»
Transposon Announces Final Results from a Phase 2 ... - Catalys …
Feb 13, 2024 TPN-101 is the first PSP treatment to reduce NfL and IL-6 levels, key biomarkers of neurodegeneration and neuroinflammation in PSP . Participants treated with TPN-101 for …See details»
Transposon Therapeutics, Inc.
Additional questions may be directed to Transposon at [email protected]. Transposon typically responds to inquiries about our Expanded Access Policy within 5 working …See details»
Transposon Therapeutics Acquired a Portfolio of Novel Nucleoside ...
[email protected]. SOURCE Transposon Therapeutics. Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences. Subscribe. …See details»
Transposon Announces Final Results from a Phase 2 ... - Lumira …
Jul 29, 2024 Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related …See details»
Transposon Announces Interim Results from a Phase 2 Study of
Nov 14, 2023 Transposon Therapeutics announced its abstract of interim results from its Phase 2 study of TPN-101 for the treatment of progressive supranuclear palsy has been accepted for …See details»
Transposon Receives US FDA Fast Track Designation for TPN-101 …
2 with PSP is 6 to 7 years. There are currently no treatments capable of delaying the progression of the disease. About Transposon Transposon Therapeutics, Inc. is a clinical-stage …See details»
About the Phase 2 Study in C9orf72-related ALS/FTD
[email protected] SOURCE Transposon Therapeutics Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences.See details»
Transposon Announces Final Results from a Phase 2 Study of
Feb 13, 2024 Final Phase 2 PSP Study Results. Final 48-week results from the Phase 2 study in PSP confirm and extend the 24-week interim results that showed TPN-101 is the first …See details»
Transposon Announces Final Results from a Phase 2 ... - Lumira …
Feb 13, 2024 TPN-101 is the first PSP treatment to reduce NfL and IL-6 levels, key biomarkers of neurodegeneration and neuroinflammation in PSP Participants treated with TPN-101 for the …See details»
Transposon Announces Final Results from a Phase 2 Study of TPN …
3 period, have been completed. Further information on the study can be accessed at ClinicalTrials.gov. About TPN-101 TPN-101 specifically inhibits the LINE-1 reverse …See details»